Conv. Plasma
Nigella Sativa

All azvudine studies
Meta analysis
study COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 37% Improvement Relative Risk Improvement 3% Azvudine for COVID-19  Han et al.  EARLY TREATMENT Is early treatment with azvudine beneficial for COVID-19? PSM retrospective 856 patients in China (December 2022 - February 2023) No significant difference in outcomes seen Han et al., Research Square, July 2023 Favors azvudine Favors control

Effectiveness and Optimal Timing of Azvudine in COVID-19 Patients: A Multi-center Retrospective Study in Beijing, China

Han et al., Research Square, doi:10.21203/
Jul 2023  
  Source   PDF   All   Meta
Azvudine for COVID-19
41st treatment shown to reduce risk in July 2023
*, now known with p = 0.00014 from 18 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
PSM retrospective 6,218 hospitalized COVID-19 patients in China showing lower 28-day all-cause mortality with azvudine treatment compared to controls (HR 0.63, 95% CI 0.40-1.00). Subgroup analysis found significantly faster clinical improvement when azvudine was initiated within 5 days of symptom onset compared to controls.
Although the 37% lower mortality is not statistically significant, it is consistent with the significant 34% lower mortality [20‑46%] from meta analysis of the 13 mortality results to date.
risk of death, 37.0% lower, HR 0.63, p = 0.048, treatment 428, control 428, propensity score matching.
risk of no improvement, 2.9% lower, HR 0.97, p = 0.73, treatment 428, control 428, inverted to make HR<1 favor treatment, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Han et al., 14 Jul 2023, retrospective, China, preprint, 22 authors, study period 10 December, 2022 - 20 February, 2023. Contact:
This PaperAzvudineAll
Effectiveness and Optimal Timing of Azvudine in COVID-19 Patients: A Multi-center Retrospective Study in Beijing, China
Xinjie Han, Xiaobo Han, Yongqian Wang, Ze Wang, Junchang Cui, Weiguo Zhao, Guoxin Mo, Yuhong Liu, Mengli Zheng, Fei Xie, Kaifei Wang, Jiguang Meng, Xin Yuan, Zhihai Han, Kun Xiao, Pan Pan, Junping Sun, Mingyue Zhang, Xinxin Zhang, Haibo Cheng, Wuxiang Xie, Lixin Xie
Background: Clinical effectiveness of Azvudine against coronavirus infection and optimal time for initiation of Azvudine treatment to hospitalized COVID-19 patients are not fully understood. Methods: This is a multi-center retrospective cohort study, and ve clinical centers of the Chinese People's Liberation Army General Hospital participated. From omicron pandemics, 6218 hospitalized patients con rmed with COVID-19 from December 10, 2022, to February 20, 2023, were retrieved for this study. After exclusions and propensity score matching , 428 Azvudine recipients and 428 controls were included with a follow-up of 28 days. The primary outcome was all-cause mortality during 28 days of hospitalization, and the secondary outcome was the proportion of patients with clinical improvement up to day 28. Results: The Azvudine group had a lower crude all-cause death rate when compared to the control group (2.82 per 1000 person-days vs. 4.52 per 1000 person-days; HR: 0.63, 95%CI: 0.40-1.00; P=0.038). Notably, the incidence rate of clinical improvement outcome was signi cantly higher in patients who received Azvudine within 5 days from the onset of symptoms, compared to the control group (Median days: 9 vs. 10; P=0.007). Subgroup analyses showed that chronic lung disease and corticosteroid treatment acted as protective factors (P=0.010; P=0.050). Conclusions: Clinical effectiveness of Azvudine in improving all-cause mortality in COVID-19 patients was seen, and initiation of Azvudine treatment within 5 days of the onset of symptoms was found to be signi cant. Additionally, the ndings revealed the protective effect of Azvudine in COVID-19 patients with chronic lung disease.
Ethical Approval This research was approved by the Ethics Committee of People's Liberation Army General Hospital (NO. 309202302230712). Informed consent was not required due to the retrospective nature of the study design. Competing interests All authors in this study declare no competing con icts. Authors' contributions Han Xinjie, Han Xiaobo, WY, WZ, XW and XL reviewed the literature, designed statistical analysis, conducted analyses, wrote the manuscript; CJ, ZW, MG, LY, Zheng Mengli, XF, WK, MJ, YX, HZ, and CH collected and analyzed clinical data, also contributed to the interpretation of the analysis; XK, PP, SJ, Zhang Mingyue and ZX prepared some paragraphs of the manuscript. All authors contributed to the interpretation of the analysis, critically reviewed and revised the manuscript, and approved the nal manuscript as submitted. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. This retrospective study was supported by China National Nature Science Foundation (82172109). Figure 4 The subgroup analysis of the effectiveness of Azvudine treatment in reducing all-cause death (A) and improving clinical improvement (B) Supplementary Files This is a list of supplementary les associated with this preprint. Click to download.
Chan, Yam, Zhang, Globally e cient non-parametric inference of average treatment effects by empirical balancing calibration weighting, J R Stat Soc Series B Stat Methodol, doi:10.1111/rssb.12129
Chang, Chen, Huang, Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2023.106834
Deng, Li, Sun, Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study, J Med Virol, doi:10.1002/jmv.28756
Deng, Li, Sun, Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study, J Med Virol, doi:10.1002/jmv.28756
Dian, Meng, Sun, Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities, J Infect, doi:10.1016/j.jinf.2023.05.012
Gal-Oz, Maier, Yoshida, ImmGen report: sexual dimorphism in the immune system transcriptome, Nat Commun, doi:10.1038/s41467-019-12348-6
Ganatra, Dani, Ahmad, Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with Covid-19, Clin Infect Dis
General O Ce, of the National Health Commission. Notice on the issuance of Diagnosis and Treatment Protocol for novel coronavirus infection (trial version 10)
Kale, Shelke, Dagar, How to use COVID-19 antiviral drugs in patients with chronic kidney disease, Front Pharmacol, doi:10.3389/fphar.2023.1053814
Liu, Chen, Lin, Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients, J Infect, doi:10.1016/j.jinf.2020.03.005
Najjar-Debbiny, Gronich, Weber, Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients, Clin Infect Dis, doi:10.1093/cid/ciac443
Radcliffe, Palacios, Azar, Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge, Am J Transplant, doi:10.1111/ajt.17098
Ren, Luo, Yu, Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study, Adv Sci (Weinh), doi:2001435.10.1002/advs.202001435
Ren, Luo, Yu, Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study, Adv Sci (Weinh), doi:2001435.10.1002/advs.202001435
Shao, Fan, Guo, Composite interventions on outcomes of severely and critically ill patients with COVID-19, doi:10.1101/2023.05.10.23289325
Silva, Abreu Cabral, Souza, Serial viral load analysis by DDPCR to evaluate FNC e cacy and safety in the treatment of mild cases of COVID-19, Front Med, doi:10.3389/fmed.2023.1143485
Sun, Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study, EClinicalMedicine, doi:10.1016/j.eclinm.2023.101981
Therneau, Grambsch, Pankratz, Penalized survival models and frailty, J Comput Graphical Stat
Xu, Yang, Zheng, The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses, J Virol, doi:10.1128/JVI.00204-20
Ye, Wang, Mao, The pathogenesis and treatment of the `Cytokine Storm' in COVID-19, J Infect, doi:10.1016/j.jinf.2020.03.037
Yu, Chang, The rst Chinese oral anti-COVID-19 drug Azvudine launched, Innovation (Camb), doi:10.1016/j.xinn.2022.100321
Zheng, Peng, Xu, Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis, J Infect, doi:10.1016/j.jinf.2020.04.021
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop